These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36358393)

  • 21. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
    Wang G; Gislum M; Filippov G; Montgomery S
    Curr Med Res Opin; 2015 Apr; 31(4):785-94. PubMed ID: 25650503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pingchan granule for depressive symptoms in parkinson's disease: A randomized, double-blind, placebo-controlled trial.
    Gu SC; Zhou J; Ye Q; Yuan CX
    J Integr Med; 2021 Mar; 19(2):120-128. PubMed ID: 33446472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson's disease.
    Chung SJ; Asgharnejad M; Bauer L; Ramirez F; Jeon B
    Expert Opin Pharmacother; 2016 Aug; 17(11):1453-61. PubMed ID: 27322571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Response and remission in depressive patients with anxiety symptoms treated with venlafaxine extended release in primary care].
    Roca Benassar M; Baca Baldomero E
    Actas Esp Psiquiatr; 2006; 34(3):162-8. PubMed ID: 16736389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and Safety of Vortioxetine for Major Depressive Disorder in Real-World Clinical Practice: Results from the Single-Arm RELIEVE China Study.
    Wang G; Xiao L; Ren H; Simonsen K; Ma J; Xu X; Guo P; Wang Z; Bai L; Heldbo Reines E; Hammer-Helmich L
    Neuropsychiatr Dis Treat; 2022; 18():1939-1950. PubMed ID: 36065389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.
    Jacobsen PL; Mahableshwarkar AR; Serenko M; Chan S; Trivedi MH
    J Clin Psychiatry; 2015 May; 76(5):575-82. PubMed ID: 26035185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine.
    Nierenberg AA; Loft H; Olsen CK
    J Affect Disord; 2019 May; 250():35-42. PubMed ID: 30826492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pingchan Granule for Motor Symptoms and Non-Motor Symptoms of Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Study.
    Gu SC; Ye Q; Wang CD; Zhao SR; Zhou J; Gao C; Zhang Y; Liu ZG; Yuan CX
    Front Pharmacol; 2022; 13():739194. PubMed ID: 35281890
    [No Abstract]   [Full Text] [Related]  

  • 29. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
    Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
    Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
    Smith KM; Eyal E; Weintraub D;
    JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of vortioxetine and sertraline for treatment of major depressive disorder in elderly patients: A double-blind randomized trial.
    Borhannejad F; Shariati B; Naderi S; Shalbafan M; Mortezaei A; Sahebolzamani E; Saeb A; Hosein Mortazavi S; Kamalzadeh L; Aqamolaei A; Ali Noorbala A; Namazi-Shabestari A; Akhondzadeh S
    J Clin Pharm Ther; 2020 Aug; 45(4):804-811. PubMed ID: 32420649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
    Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD).
    Chokka P; Bougie J; Rampakakis E; Proulx J
    CNS Spectr; 2019 Jun; 24(3):338-347. PubMed ID: 29792585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR; Jacobsen PL; Chen Y
    Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Other Antidepressants.
    Schwasinger-Schmidt TE; Macaluso M
    Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA).
    Chin CN; Zain A; Hemrungrojn S; Ung EK; Kwansanit P; Au Yong KC; Chong MSW; Inpa C; Yen TH; Yeoh BBD; Tay LK; Bernardo C; Lim LC; Yap CH; Fones C; Nayak A; Nelleman L
    Curr Med Res Opin; 2018 Nov; 34(11):1975-1984. PubMed ID: 29768955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study.
    Mattingly GW; Ren H; Christensen MC; Katzman MA; Polosan M; Simonsen K; Hammer-Helmich L
    Front Psychiatry; 2022; 13():824831. PubMed ID: 35356713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Re-evaluation of the definition of remission on the 17-item Hamilton Depression Rating Scale based on recovery in health-related quality of life in an observational post-marketing study.
    Sawamura J; Ishigooka J; Nishimura K
    Health Qual Life Outcomes; 2018 Jan; 16(1):14. PubMed ID: 29338728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a "real-world" chart review study.
    De Berardis D; Fornaro M; Anastasia A; Vellante F; Olivieri L; Rapini G; Serroni N; Orsolini L; Valchera A; Carano A; Tomasetti C; Ventriglio A; Bustini M; Pompili M; Serafini G; Perna G; Iasevoli F; Martinotti G; Di Giannantonio M
    Braz J Psychiatry; 2020; 42(3):317-321. PubMed ID: 32159712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder.
    Nishimura A; Aritomi Y; Sasai K; Kitagawa T; Mahableshwarkar AR
    Psychiatry Clin Neurosci; 2018 Feb; 72(2):64-72. PubMed ID: 28858412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.